Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 11, 2007 - Issue 11
Submit an article Journal homepage
687
Views
69
CrossRef citations to date
0
Altmetric
Review

Glutamate excitotoxicity and therapeutic targets for amyotrophic lateral sclerosis

Juan C Corona Universidad Nacional Autönoma de México, Departamento de Neurociencias, Instituto de Fisiología Celular, AP 70-253, 04510-México, D.F., México +52 55 56225642; +52 55 56225607; [email protected]
, PhD,
Luis B Tovar-y-Romo Universidad Nacional Autönoma de México, Departamento de Neurociencias, Instituto de Fisiología Celular, AP 70-253, 04510-México, D.F., México +52 55 56225642; +52 55 56225607; [email protected]
, BSc &
Ricardo Tapia Universidad Nacional Autönoma de México, Departamento de Neurociencias, Instituto de Fisiología Celular, AP 70-253, 04510-México, D.F., México +52 55 56225642; +52 55 56225607; [email protected]
, MD PhD
Pages 1415-1428 | Published online: 26 Oct 2007

Bibliography

  • ROSEN DR, SIDDIQUE T, PATTERSON D et al.: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362:59-62.
  • CHANCELLOR AM, WARLOW CP: Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950. J. Neurol. Neurosurg. Psychiatry (1992) 55:1106-1115.
  • ARUNDINE M, TYMIANSKI M: Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium (2003) 34:325-337.
  • LIPTON SA, ROSENBERG PA: Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. (1994) 330:613-622.
  • TAPIA R, MEDINA-CEJA L, PEÑA F: On the relationship between extracellular glutamate, hyperexcitation and neurodegeneration, in vivo. Neurochem. Int. (1999) 34:23-31.
  • MELDRUM BS: Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J. Nutr. (2000) 130:S1007-S1015.
  • BOILLEE S, VANDE VELDE C, CLEVELAND DW: ALS: a disease of motor neurons and their non-neuronal neighbors. Neuron (2006) 52:39-59.
  • ROWLAND LP, SHNEIDER NA: Amyotrophic lateral sclerosis. N. Engl. J. Med. (2001) 344:1688-1700.
  • BRUIJN LI, MILLER TM, CLEVELAND DW: Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. (2004) 27:723-749.
  • JULIEN JP: Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. Cell (2001) 104:581-591.
  • SHAW PJ: Molecular and cellular pathways of neurodegeneration in motor neurone disease. J. Neurol. Neurosurg. Psychiatry (2005) 76:1046-1057.
  • HOLLMANN M, HEINEMANN S: Cloned glutamate receptors. Annu. Rev. Neurosci. (1994) 17:31-108.
  • BETTLER B, MULLE C: Review: neurotransmitter receptors. II. AMPA and kainate receptors. Neuropharmacology (1995) 34:123-139.
  • PIN JP, DUVOISIN R: The metabotropic glutamate receptors: structure and functions. Neuropharmacology (1995) 34:1-26.
  • KANNER BI: Ion-coupled neurotransmitter transport. Curr. Opin. Cell Biol. (1989) 1:735-738.
  • GADEA A, LOPEZ-COLOME AM: Glial transporters for glutamate, glycine and GABA I. Glutamate transporters. J. Neurosci. Res. (2001) 63:453-460.
  • DANBOLT NC: Glutamate uptake. Prog. Neurobiol. (2001) 65:1-105.
  • TANAKA K, WATASE K, MANABE T et al.: Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science (1997) 276:1699-1702.
  • ROTHSTEIN JD, MARTIN LJ, KUNCL RW: Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. (1992) 326:1464-1468.
  • ROTHSTEIN JD, VAN KAMMEN M, LEVEY AI, MARTIN LJ, KUNCL RW: Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. (1995) 38:73-84.
  • SHAW PJ, FORREST V, INCE PG, RICHARDSON JP, WASTELL HJ: CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration (1995) 4:209-216.
  • SPREUX-VAROQUAUX O, BENSIMON G, LACOMBLEZ L et al.: Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J. Neurol. Sci. (2002) 193:73-78.
  • CORONA JC, TAPIA R: AMPA receptor activation, but not the accumulation of endogenous extracellular glutamate, induces paralysis and motor neuron death in rat spinal cord in vivo. J. Neurochem. (2004) 89:988-997.
  • TOVAR-Y-ROMO LB, TAPIA R: Cerebral neurons of transgenic ALS mice are vulnerable to glutamate release stimulation but not to increased extracellular glutamate due to transport blockade. Exp. Neurol. (2006) 199:281-290.
  • AYALA GX, TAPIA R: Late N-methyl-D-aspartate receptor blockade rescues hippocampal neurons from excitotoxic stress and death after 4-aminopyridine-induced epilepsy. Eur. J. Neurosci. (2005) 22:3067-3076.
  • AYALA GX, TAPIA R: Expression of heat shock protein 70 induced by 4-aminopyridine through glutamate-mediated excitotoxic stress in rat hippocampus in vivo. Neuropharmacology (2003) 45:649-660.
  • PEÑA F, TAPIA R: Seizures and neurodegeneration induced by 4-aminopyridine in rat hippocampus in vivo: role of glutamate- and GABA-mediated neurotransmission and of ion channels. Neuroscience (2000) 101:547-561.
  • HUME RI, DINGLEDINE R, HEINEMANN SF: Identification of a site in glutamate receptor subunits that controls calcium permeability. Science (1991) 253:1028-1031.
  • HOLLMANN M, HARTLEY M, HEINEMANN S: Ca2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science (1991) 252:851-853.
  • BURNASHEV N, MONYER H, SEEBURG PH, SAKMANN B: Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron (1992) 8:189-198.
  • CHOI DW: Glutamate neurotoxicity and diseases of the nervous system. Neuron (1988) 1:623-634.
  • COYLE JT, PUTTFARCKEN P: Oxidative stress, glutamate, and neurodegenerative disorders. Science (1993) 262:689-695.
  • CELIO MR: Calbindin D-28k and parvalbumin in the rat nervous system. Neuroscience (1990) 35:375-475.
  • PALECEK J, LIPS MB, KELLER BU: Calcium dynamics and buffering in motoneurones of the mouse spinal cord. J. Physiol. (1999) (520 Part 2):485-502.
  • INCE P, STOUT N, SHAW P et al.: Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol. Appl. Neurobiol. (1993) 19:291-299.
  • ALEXIANU ME, HO BK, MOHAMED AH et al.: The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann. Neurol. (1994) 36:846-858.
  • SASAKI S, WARITA H, KOMORI T et al.: Parvalbumin and calbindin D-28k immunoreactivity in transgenic mice with a G93A mutant SOD1 gene. Brain Res. (2006) 1083:196-203.
  • SIKLÓS L, ENGELHARDT JI, ALEXIANU ME et al.: Intracellular calcium parallels motoneuron degeneration in SOD-1 mutant mice. J. Neuropathol. Exp. Neurol. (1998) 57:571-587.
  • GROSSKREUTZ J, HAASTERT K, DEWIL M et al.: Role of mitochondria in kainate-induced fast Ca2+ transients in cultured spinal motor neurons. Cell Calcium (2007) 42:59-69.
  • JAHN K, GROSSKREUTZ J, HAASTERT K et al.: Temporospatial coupling of networked synaptic activation of AMPA-type glutamate receptor channels and calcium transients in cultured motoneurons. Neuroscience (2006) 142:1019-1029.
  • CARRIEDO SG, YIN HZ, WEISS JH: Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J. Neurosci. (1996) 16:4069-4079.
  • WILLIAMS TL, DAY NC, INCE PG, KAMBOJ RK, SHAW PJ: Calcium-permeable α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann. Neurol. (1997) 42:200-207.
  • VAN DEN BOSCH L, VANDENBERGHE W, KLAASSEN H, VAN HOUTTE E, ROBBERECHT W: Ca2+-permeable AMPA receptors and selective vulnerability of motor neurons. J. Neurol. Sci. (2000) 180:29-34.
  • GREIG A, DONEVAN SD, MUJTABA TJ, PARKS TN, RAO MS: Characterization of the AMPA-activated receptors present on motoneurons. J. Neurochem. (2000) 74:179-191.
  • VAN DAMME P, VAN DEN BOSCH L, VAN HOUTTE E, CALLEWAERT G, ROBBERECHT W: GluR2-dependent properties of AMPA receptors determine the selective vulnerability of motor neurons to excitotoxicity. J. Neurophysiol. (2002) 88:1279-1287.
  • TOMIYAMA M, RODRIGUEZ-PUERTAS R, CORTES R et al.: Differential regional distribution of AMPA receptor subunit messenger RNAs in the human spinal cord as visualized by in situ hybridization. Neuroscience (1996) 75:901-915.
  • VIRGO L, SAMARASINGHE S, DE BELLEROCHE J: Analysis of AMPA receptor subunit mRNA expression in control and ALS spinal cord. Neuroreport (1996) 7:2507-2511.
  • BAR-PELED O, O'BRIEN RJ, MORRISON JH, ROTHSTEIN JD: Cultured motor neurons possess calcium-permeable AMPA/kainate receptors. Neuroreport (1999) 10:855-859.
  • KAWAHARA Y, KWAK S, SUN H et al.: Human spinal motoneurons express low relative abundance of GluR2 mRNA: an implication for excitotoxicity in ALS. J. Neurochem. (2003) 85:680-689.
  • TAKUMA H, KWAK S, YOSHIZAWA T, KANAZAWA I: Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann. Neurol. (1999) 46:806-815.
  • KAWAHARA Y, ITO K, SUN H et al.: Glutamate receptors: RNA editing and death of motor neurons. Nature (2004) 427:801.
  • KWAK S, KAWAHARA Y: Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J. Mol. Med. (2005) 83:110-120.
  • KAWAHARA Y, SUN H, ITO K et al.: Underediting of GluR2 mRNA, a neuronal death inducing molecular change in sporadic ALS, does not occur in motor neurons in ALS1 or SBMA. Neurosci. Res. (2006) 54:11-14.
  • GURNEY ME, PU H, CHIU AY et al.: Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science (1994) 264:1772-1775.
  • NAGAI M, AOKI M, MIYOSHI I et al.: Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J. Neurosci. (2001) 21:9246-9254.
  • HOWLAND DS, LIU J, SHE Y et al.: Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. USA (2002) 99:1604-1609.
  • KOIKE M, IINO M, OZAWA S: Blocking effect of 1-naphthyl acetyl spermine on Ca2+-permeable AMPA receptors in cultured rat hippocampal neurons. Neurosci. Res. (1997) 29:27-36.
  • NOH KM, YOKOTA H, MASHIKO T et al.: Blockade of calcium-permeable AMPA receptors protects hippocampal neurons against global ischemia-induced death. Proc. Natl. Acad. Sci. USA (2005) 102:12230-12235.
  • YIN HZ, SENSI SL, OGOSHI F, WEISS JH: Blockade of Ca2+-permeable AMPA/kainate channels decreases oxygen-glucose deprivation-induced Zn2+ accumulation and neuronal loss in hippocampal pyramidal neurons. J. Neurosci. (2002) 22:1273-1279.
  • CORONA JC, TAPIA R: Ca2+-permeable AMPA receptors and intracellular Ca2+ determine motoneuron vulnerability in rat spinal cord in vivo. Neuropharmacology (2007) 52:1219-1228.
  • TOVAR-Y-ROMO LB, ZEPEDA A, TAPIA R: Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration. J. Neuropathol. Exp. Neurol. (2007) 66:913-922.
  • DOBLE A: The pharmacology and mechanism of action of riluzole. Neurology (1996) 47:S233-S241.
  • LACOMBLEZ L, BENSIMON G, LEIGH PN, GUILLET P, MEININGER V: Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole study group II. Lancet (1996) 347:1425-1431.
  • BENSIMON G, LACOMBLEZ L, MEININGER V: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/riluzole study group. N. Engl. J. Med. (1994) 330:585-591.
  • BENSIMON G, LACOMBLEZ L, DELUMEAU JC et al.: A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J. Neurol. (2002) 249:609-615.
  • LACOMBLEZ L, BENSIMON G, LEIGH PN et al.: Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2002) 3:23-29.
  • GURNEY ME, CUTTING FB, ZHAI P et al.: Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. (1996) 39:147-157.
  • KUO JJ, SIDDIQUE T, FU R, HECKMAN CJ: Increased persistent Na+ current and its effect on excitability in motoneurones cultured from mutant SOD1 mice. J. Physiol. (2005) 563:843-854.
  • SKRADSKI S, WHITE HS: Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia (2000) 41:S45-S47.
  • MARAGAKIS NJ, JACKSON M, GANEL R, ROTHSTEIN JD: Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice. Neurosci. Lett. (2003) 338:107-110.
  • CUDKOWICZ ME, SHEFNER JM, SCHOENFELD DA et al.: A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology (2003) 61:456-464.
  • LANGAN YM, LUCAS R, JEWELL H et al.: Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia (2003) 44:46-53.
  • ROTHSTEIN JD, PATEL S, REGAN MR et al.: β-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature (2005) 433:73-77.
  • PARDO AC, WONG V, BENSON LM et al.: Loss of the astrocyte glutamate transporter GLT1 modifies disease in SOD1(G93A) mice. Exp. Neurol. (2006) 201:120-130.
  • VON LEWINSKI F, KELLER BU: Ca2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends Neurosci. (2005) 28:494-500.
  • MANFREDI G, XU Z: Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion (2005) 5:77-87.
  • MENZIES FM, INCE PG, SHAW PJ: Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem. Int. (2002) 40:543-551.
  • SWERDLOW RH, PARKS JK, CASSARINO DS et al.: Mitochondria in sporadic amyotrophic lateral sclerosis. Exp. Neurol. (1998) 153:135-142.
  • KLIVENYI P, FERRANTE RJ, MATTHEWS RT et al.: Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. (1999) 5:347-350.
  • ZHANG W, NARAYANAN M, FRIEDLANDER RM: Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol. (2003) 53:267-270.
  • PARK JH, HONG YH, KIM HJ et al.: Pyruvate slows disease progression in a G93A SOD1 mutant transgenic mouse model. Neurosci. Lett. (2007) 413:265-269.
  • SHEFNER JM, CUDKOWICZ ME, SCHOENFELD D et al.: A clinical trial of creatine in ALS. Neurology (2004) 63:1656-1661.
  • MATTHEWS RT, YANG L, BROWNE S, BAIK M, BEAL MF: Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. USA (1998) 95:8892-8897.
  • LEVY G, KAUFMANN P, BUCHSBAUM R et al.: A two-stage design for a Phase II clinical trial of coenzyme Q10 in ALS. Neurology (2006) 66:660-663.
  • FERRANTE KL, SHEFNER J, ZHANG H et al.: Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology (2005) 65:1834-1836.
  • CARRIEDO SG, SENSI SL, YIN HZ, WEISS JH: AMPA exposures induce mitochondrial Ca2+ overload and ROS generation in spinal motor neurons in vitro. J. Neurosci. (2000) 20:240-250.
  • RAO SD, YIN HZ, WEISS JH: Disruption of glial glutamate transport by reactive oxygen species produced in motor neurons. J. Neurosci. (2003) 23:2627-2633.
  • ABE K, PAN LH, WATANABE M et al.: Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis. Neurol. Res. (1997) 19:124-128.
  • BEAL MF, FERRANTE RJ, BROWNE SE et al.: Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol. (1997) 42:644-654.
  • FERRANTE RJ, BROWNE SE, SHINOBU LA et al.: Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. (1997) 69:2064-2074.
  • SHAW PJ, INCE PG, FALKOUS G, MANTLE D: Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann. Neurol. (1995) 38:691-695.
  • BOGDANOV M, BROWN RH, MATSON W et al.: Increased oxidative damage to DNA in ALS patients. Free Radic. Biol. Med. (2000) 29:652-658.
  • DESNUELLE C, DIB M, GARREL C, FAVIER A: A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol study group. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2001) 2:9-18.
  • GRAF M, ECKER D, HOROWSKI R et al.: High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J. Neural. Transm. (2005) 112:649-660.
  • LOUWERSE ES, WEVERLING GJ, BOSSUYT PM, MEYJES FE, DE JONG JM: Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch. Neurol. (1995) 52:559-564.
  • ANDREASSEN OA, DEDEOGLU A, KLIVENYI P, BEAL MF, BUSH AI: N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport (2000) 11:2491-2493.
  • LANGE DJ, MURPHY PL, DIAMOND B et al.: Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch. Neurol. (1998) 55:93-96.
  • CROW JP, CALINGASAN NY, CHEN J, HILL JL, BEAL MF: Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann. Neurol. (2005) 58:258-265.
  • ORRELL RW: AEOL-10150 (Aeolus). Curr. Opin. Investig. Drugs (2006) 7:70-80.
  • KOTZBAUER PT, HOLTZMAN DM: Expectations and challenges in the therapeutic use of neurotrophic factors. Ann. Neurol. (2006) 59:444-447.
  • SENDTNER M, SCHMALBRUCH H, STOCKLI KA et al.: Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature (1992) 358:502-504.
  • MITSUMOTO H, IKEDA K, HOLMLUND T et al.: The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann. Neurol. (1994) 36:142-148.
  • A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF treatment study group. Neurology (1996) 46:1244-1249.
  • A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF study group (Phase III). Neurology (1999) 52:1427-1433.
  • BORASIO GD, ROBBERECHT W, LEIGH PN et al.: A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I study group. Neurology (1998) 51:583-586.
  • LAI EC, FELICE KJ, FESTOFF BW et al.: Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I study group. Neurology (1997) 49:1621-1630.
  • AZZOUZ M, RALPH GS, STORKEBAUM E et al.: VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 429:413-417.
  • KASPAR BK, LLADO J, SHERKAT N, ROTHSTEIN JD, GAGE FH: Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science (2003) 301:839-842.
  • WANG LJ, LU YY, MURAMATSU S et al.: Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurosci. (2002) 22:6920-6928.
  • STORKEBAUM E, LAMBRECHTS D, DEWERCHIN M et al.: Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. (2005) 8:85-92.
  • WANG Y, MAO XO, XIE L et al.: Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J. Neurosci. (2007) 27:304-307.
  • ZHENG C, NENNESMO I, FADEEL B, HENTER JI: Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. (2004) 56:564-567.
  • OOSTHUYSE B, MOONS L, STORKEBAUM E et al.: Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. (2001) 28:131-138.
  • LAMBRECHTS D, STORKEBAUM E, MORIMOTO M et al.: VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. (2003) 34:383-394.
  • LI B, XU W, LUO C, GOZAL D, LIU R: VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Mol. Brain Res. (2003) 111:155-164.
  • NEWBERN J, TAYLOR A, ROBINSON M, LI L, MILLIGAN CE: Decreases in phosphoinositide-3-kinase/Akt and extracellular signal-regulated kinase 1/2 signaling activate components of spinal motoneuron death. J. Neurochem. (2005) 94:1652-1665.
  • YU F, SUGAWARA T, MAIER CM, HSIEH LB, CHAN PH: Akt/Bad signaling and motor neuron survival after spinal cord injury. Neurobiol. Dis. (2005) 20:491-499.
  • MATSUZAKI H, TAMATANI M, YAMAGUCHI A et al.: Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades. Faseb J. (2001) 15:1218-1220.
  • BROWN RH Jr: Superoxide dismutase in familial amyotrophic lateral sclerosis: models for gain of function. Curr. Opin. Neurobiol. (1995) 5:841-846.
  • REAUME AG, ELLIOTT JL, HOFFMAN EK et al.: Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. (1996) 13:43-47.
  • RALPH GS, RADCLIFFE PA, DAY DM et al.: Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. (2005) 11:429-433.
  • RAOUL C, ABBAS-TERKI T, BENSADOUN JC et al.: Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. (2005) 11:423-428.
  • XIA X, ZHOU H, HUANG Y, XU Z: Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol. Dis. (2006) 23:578-586.
  • SCHWARZ DS, DING H, KENNINGTON L et al.: Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet. (2006) 2:E140.
  • XIA XG, ZHOU H, ZHOU S et al.: An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase. J. Neurochem. (2005) 92:362-367.
  • URUSHITANI M, SIK A, SAKURAI T et al.: Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci. (2006) 9:108-118.
  • TURNER BJ, ATKIN JD, FARG MA et al.: Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis. J. Neurosci. (2005) 25:108-117.
  • URUSHITANI M, EZZI SA, JULIEN JP: Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA (2007) 104:2495-2500.
  • HENKEL JS, ENGELHARDT JI, SIKLOS L et al.: Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. (2004) 55:221-235.
  • KAWAMATA T, AKIYAMA H, YAMADA T, MCGEER PL: Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. (1992) 140:691-707.
  • TURNER MR, CAGNIN A, TURKHEIMER FE et al.: Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. (2004) 15:601-609.
  • HENKEL JS, BEERS DR, SIKLOS L, APPEL SH: The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol. Cell Neurosci. (2006) 31:427-437.
  • SARGSYAN SA, MONK PN, SHAW PJ: Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia (2005) 51:241-253.
  • WEST M, MHATRE M, CEBALLOS A et al.: The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor α activation of microglia and extends survival of G93A-SOD1 transgenic mice. J. Neurochem. (2004) 91:133-143.
  • YRJANHEIKKI J, TIKKA T, KEINANEN R et al.: A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. USA (1999) 96:13496-13500.
  • TIKKA TM, VARTIAINEN NE, GOLDSTEINS G et al.: Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain (2002) 125:722-731.
  • KRIZ J, NGUYEN MD, JULIEN JP: Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. (2002) 10:268-278.
  • VAN DEN BOSCH L, TILKIN P, LEMMENS G, ROBBERECHT W: Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport (2002) 13:1067-1070.
  • ZHU S, STAVROVSKAYA IG, DROZDA M et al.: Minocycline inhibits cytochrome C release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 417:74-78.
  • SATHASIVAM S, GRIERSON AJ, SHAW PJ: Characterization of the caspase cascade in a cell culture model of SOD1-related familial amyotrophic lateral sclerosis: expression, activation and therapeutic effects of inhibition. Neuropathol. Appl. Neurobiol. (2005) 31:467-485.
  • SHOEMAKER JL, SEELY KA, REED RL, CROW JP, PRATHER PL: The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem. (2007) 101:87-98.
  • LINO MM, SCHNEIDER C, CARONI P: Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. (2002) 22:4825-4832.
  • PRAMATAROVA A, LAGANIERE J, ROUSSEL J, BRISEBOIS K, ROULEAU GA: Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. (2001) 21:3369-3374.
  • GONG YH, PARSADANIAN AS, ANDREEVA A, SNIDER WD, ELLIOTT JL: Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. (2000) 20:660-665.
  • VANDENBERGHE W, VAN DEN BOSCH L, ROBBERECHT W: Glial cells potentiate kainate-induced neuronal death in a motoneuron-enriched spinal coculture system. Brain Res. (1998) 807:1-10.
  • DI GIORGIO FP, CARRASCO MA, SIAO MC, MANIATIS T, EGGAN K: Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. (2007) 10:608-614.
  • NAGAI M, RE DB, NAGATA T et al.: Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. (2007) 10:615-622.
  • CLEMENT AM, NGUYEN MD, ROBERTS EA et al.: Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science (2003) 302:113-117.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.